Remicade (infliximab) Drug Market Report

Global Remicade (infliximab) Drug Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 12, 2022
  • PAGES：195
  • REPORT CODE：GMM815631
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Remicade (infliximab) Drug market report explains the definition, types, applications, major countries, and major players of the Remicade (infliximab) Drug market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Celltrion Healthcare

    • Hospira

    • Epirus Biopharmaceuticals

    • Janssen

    • Samsung Bioepsis

    By Type:

    • Brands Drugs

    • Generic Drugs

    By End-User:

    • Crohn's Disease

    • Pediatric Crohn's Disease

    • Ulcerative Colitis

    • Pediatric Ulcerative Colitis

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Remicade (infliximab) Drug Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Remicade (infliximab) Drug Outlook to 2028- Original Forecasts

    • 2.2 Remicade (infliximab) Drug Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Remicade (infliximab) Drug Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Remicade (infliximab) Drug Market- Recent Developments

    • 6.1 Remicade (infliximab) Drug Market News and Developments

    • 6.2 Remicade (infliximab) Drug Market Deals Landscape

    7 Remicade (infliximab) Drug Raw Materials and Cost Structure Analysis

    • 7.1 Remicade (infliximab) Drug Key Raw Materials

    • 7.2 Remicade (infliximab) Drug Price Trend of Key Raw Materials

    • 7.3 Remicade (infliximab) Drug Key Suppliers of Raw Materials

    • 7.4 Remicade (infliximab) Drug Market Concentration Rate of Raw Materials

    • 7.5 Remicade (infliximab) Drug Cost Structure Analysis

      • 7.5.1 Remicade (infliximab) Drug Raw Materials Analysis

      • 7.5.2 Remicade (infliximab) Drug Labor Cost Analysis

      • 7.5.3 Remicade (infliximab) Drug Manufacturing Expenses Analysis

    8 Global Remicade (infliximab) Drug Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Remicade (infliximab) Drug Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Remicade (infliximab) Drug Export by Region (Top 10 Countries) (2017-2028)

    9 Global Remicade (infliximab) Drug Market Outlook by Types and Applications to 2022

    • 9.1 Global Remicade (infliximab) Drug Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Brands Drugs Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Generic Drugs Consumption and Growth Rate (2017-2022)

    • 9.2 Global Remicade (infliximab) Drug Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Crohn's Disease Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pediatric Crohn's Disease Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Pediatric Ulcerative Colitis Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Remicade (infliximab) Drug Market Analysis and Outlook till 2022

    • 10.1 Global Remicade (infliximab) Drug Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.2.2 Canada Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.2.3 Mexico Remicade (infliximab) Drug Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.2 UK Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.3 Spain Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.4 Belgium Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.5 France Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.6 Italy Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.7 Denmark Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.8 Finland Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.9 Norway Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.10 Sweden Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.11 Poland Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.12 Russia Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.3.13 Turkey Remicade (infliximab) Drug Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.2 Japan Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.3 India Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.4 South Korea Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.5 Pakistan Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.6 Bangladesh Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.7 Indonesia Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.8 Thailand Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.9 Singapore Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.10 Malaysia Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.11 Philippines Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.4.12 Vietnam Remicade (infliximab) Drug Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.5.2 Colombia Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.5.3 Chile Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.5.4 Argentina Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.5.5 Venezuela Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.5.6 Peru Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.5.7 Puerto Rico Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.5.8 Ecuador Remicade (infliximab) Drug Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.6.2 Kuwait Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.6.3 Oman Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.6.4 Qatar Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Remicade (infliximab) Drug Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.7.2 South Africa Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.7.3 Egypt Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.7.4 Algeria Remicade (infliximab) Drug Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Remicade (infliximab) Drug Consumption (2017-2022)

      • 10.8.2 New Zealand Remicade (infliximab) Drug Consumption (2017-2022)

    11 Global Remicade (infliximab) Drug Competitive Analysis

    • 11.1 Celltrion Healthcare

      • 11.1.1 Celltrion Healthcare Company Details

      • 11.1.2 Celltrion Healthcare Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Celltrion Healthcare Remicade (infliximab) Drug Main Business and Markets Served

      • 11.1.4 Celltrion Healthcare Remicade (infliximab) Drug Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Hospira

      • 11.2.1 Hospira Company Details

      • 11.2.2 Hospira Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Hospira Remicade (infliximab) Drug Main Business and Markets Served

      • 11.2.4 Hospira Remicade (infliximab) Drug Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Epirus Biopharmaceuticals

      • 11.3.1 Epirus Biopharmaceuticals Company Details

      • 11.3.2 Epirus Biopharmaceuticals Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Epirus Biopharmaceuticals Remicade (infliximab) Drug Main Business and Markets Served

      • 11.3.4 Epirus Biopharmaceuticals Remicade (infliximab) Drug Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Janssen

      • 11.4.1 Janssen Company Details

      • 11.4.2 Janssen Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Janssen Remicade (infliximab) Drug Main Business and Markets Served

      • 11.4.4 Janssen Remicade (infliximab) Drug Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Samsung Bioepsis

      • 11.5.1 Samsung Bioepsis Company Details

      • 11.5.2 Samsung Bioepsis Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Samsung Bioepsis Remicade (infliximab) Drug Main Business and Markets Served

      • 11.5.4 Samsung Bioepsis Remicade (infliximab) Drug Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Remicade (infliximab) Drug Market Outlook by Types and Applications to 2028

    • 12.1 Global Remicade (infliximab) Drug Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Brands Drugs Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Generic Drugs Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Remicade (infliximab) Drug Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Pediatric Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Pediatric Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Remicade (infliximab) Drug Market Analysis and Outlook to 2028

    • 13.1 Global Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.2.2 Canada Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.2 UK Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.3 Spain Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.5 France Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.6 Italy Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.8 Finland Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.9 Norway Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.11 Poland Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.12 Russia Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.2 Japan Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.3 India Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.5.3 Chile Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.5.6 Peru Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.6.3 Oman Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Remicade (infliximab) Drug Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Remicade (infliximab) Drug Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Remicade (infliximab) Drug

    • Figure of Remicade (infliximab) Drug Picture

    • Table Global Remicade (infliximab) Drug Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Remicade (infliximab) Drug Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Brands Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Generic Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Crohn's Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Pediatric Crohn's Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)

    • Figure Global Pediatric Ulcerative Colitis Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Table North America Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Figure United States Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Canada Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Mexico Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Table Europe Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Figure Germany Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure UK Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Spain Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Belgium Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure France Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Italy Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Denmark Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Finland Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Norway Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Sweden Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Poland Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Russia Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Turkey Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Table APAC Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Figure China Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Japan Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure India Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure South Korea Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Thailand Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Singapore Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Philippines Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Table South America Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Figure Brazil Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Colombia Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Chile Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Argentina Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Peru Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Table GCC Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Figure Bahrain Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Oman Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Qatar Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Table Africa Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Figure Nigeria Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure South Africa Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Egypt Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure Algeria Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Table Oceania Remicade (infliximab) Drug Consumption by Country (2017-2022)

    • Figure Australia Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Remicade (infliximab) Drug Consumption and Growth Rate (2017-2022)

    • Table Celltrion Healthcare Company Details

    • Table Celltrion Healthcare Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Healthcare Remicade (infliximab) Drug Main Business and Markets Served

    • Table Celltrion Healthcare Remicade (infliximab) Drug Product Portfolio

    • Table Hospira Company Details

    • Table Hospira Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hospira Remicade (infliximab) Drug Main Business and Markets Served

    • Table Hospira Remicade (infliximab) Drug Product Portfolio

    • Table Epirus Biopharmaceuticals Company Details

    • Table Epirus Biopharmaceuticals Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Epirus Biopharmaceuticals Remicade (infliximab) Drug Main Business and Markets Served

    • Table Epirus Biopharmaceuticals Remicade (infliximab) Drug Product Portfolio

    • Table Janssen Company Details

    • Table Janssen Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Janssen Remicade (infliximab) Drug Main Business and Markets Served

    • Table Janssen Remicade (infliximab) Drug Product Portfolio

    • Table Samsung Bioepsis Company Details

    • Table Samsung Bioepsis Remicade (infliximab) Drug Sales, Price, Value and Gross Profit (2017-2022)

    • Table Samsung Bioepsis Remicade (infliximab) Drug Main Business and Markets Served

    • Table Samsung Bioepsis Remicade (infliximab) Drug Product Portfolio

    • Figure Global Brands Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Generic Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pediatric Crohn's Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pediatric Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Table North America Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Figure United States Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Figure Germany Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Figure China Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Figure Brazil Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Remicade (infliximab) Drug Consumption Forecast by Country (2022-2028)

    • Figure Australia Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Remicade (infliximab) Drug Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US